Ardelyx announced on October 15, 2024, that additional data supporting XPHOZAH (tenapanor) would be presented at the American Society of Nephrology’s (ASN) Kidney Week, held from October 24-27, 2024. XPHOZAH is approved to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis.
The presentations include two poster sessions on October 24, 2024. One poster, titled 'Sustained Phosphate Reduction Assessed by P AUC With Tenapanor Is Associated With Reduced Fibroblast Growth Factor 23,' highlights XPHOZAH's impact on a key biomarker.
A second poster, 'Tenapanor Reduces Serum Phosphate With Similar Efficacy and Tolerability Profiles When Added to Various Phosphate Binders,' demonstrates the drug's consistent performance. Ardelyx also sponsored an Exhibitor Spotlight on October 25, 2024, to discuss hyperphosphatemia management.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.